Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 6/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | TK1 | P04183 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31289405 | 1.00 | TOP2A (0.66) | TOP2APOLBTK1 | |
| SCHEMBL22315382 | 1.00 | TOP2A (0.66) | TOP2APOLBTK1 | |
| SCHEMBL21489337 | 1.00 | TOP2A (0.66) | TOP2APOLBTK1 | |
| SCHEMBL12570184 | 1.00 | TOP2A (0.66) | TOP2APOLBTK1 | |
| SCHEMBL888123 | 1.00 | TOP2A (0.66) | TOP2APOLBTK1 | |
| SCHEMBL30965353 | 0.90 | POLB (0.59) | TOP2APOLBTK1 | |
| SCHEMBL8987846 | 0.89 | POLB (0.57) | TOP2APOLBTK1 | |
| SCHEMBL2120098 | 0.89 | TK1 (0.66) | TOP2APOLBTK1 | |
| SCHEMBL8691895 | 0.89 | LMNA (0.66) | TOP2A | |
| SCHEMBL20417805 | 0.89 | TK1 (0.66) | TOP2APOLBTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503730-B2 | Detectable nucleotide analogues | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250236911-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-07-24 | — | — | US | disclosed |
| US-12337009-B2 | Nucleotide derivatives and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250154580-A1 | ENZYME TRANSLOCATORS IN NANOGAP WITH 3' -ESTERS | ROBERT BOSCH GMBH (DE) | 2025-05-15 | — | — | US | disclosed |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| CN-119431453-A | Phosphorus (V) based reagent, method for the production thereof, and use thereof for producing stereoregular organic phosphorus (V) compounds | 百时美施贵宝公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20250042932-A1 | METHOD FOR PRODUCING POLYNUCLEOTIDES | ATDBio Limited (GB) | 2025-02-06 | — | — | US | disclosed |
| EP-4493573-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | Rome Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12195493-B2 | Reversibly blocked nucleoside analogues and their use | MGI TECH CO., LTD. (CN) | 2025-01-14 | — | — | US | disclosed |
| US-12187758-B2 | Compounds and methods for treating disease | ROME THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-0753002-A1 | MODIFIED OLIGONUCLEOTIDES AND INTERMEDIATES USEFUL IN NUCLEIC ACID THERAPEUTICS | AMGEN INC. (US) | 1997-01-15 | — | — | EP | disclosed |
| EP-0611075-B1 | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use | SANKYO CO (JP) | 1996-12-18 | — | — | EP | disclosed |
| EP-0649429-A4 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES. | ISIS PHARMACEUTICALS INC (US) | 1996-04-10 | — | — | EP | disclosed |
| US-5489677-A | NUCLEASE RESISTANT OLIGONUCLEOTIDE ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 1996-02-06 | — | — | US | disclosed |
| WO-1995026972-A1 | MODIFIED OLIGONUCLEOTIDES AND INTERMEDIATES USEFUL IN NUCLEIC ACID THERAPEUTICS | AMGEN INC. (US) | 1995-10-12 | — | — | WO | disclosed |
| EP-0649429-A1 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1995-04-26 | — | — | EP | disclosed |
| US-5386023-A | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling | ISIS PHARMACEUTICALS (US) | 1995-01-31 | — | — | US | disclosed |
| EP-0611075-A1 | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1994-08-17 | — | — | EP | disclosed |
| WO-1994000467-A1 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1994-01-06 | — | — | WO | disclosed |
| EP-0216357-A2 | Phosphoramidite compounds and process for production thereof | NIPPON ZEON CO., LTD. (JP) | 1987-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236911-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | RNGTT, POLRMT, MTR | TOP2A 181/4885POLB 22/4885TK1 112/4885 |
| US-12337009-B2 | Nucleotide derivatives and methods of use thereof | POLRMT, NSUN2, NUDT1 | TOP2A 238/4885POLB 11/4885TK1 244/4885 |
| US-20250042932-A1 | METHOD FOR PRODUCING POLYNUCLEOTIDES | POLN, RNGTT, PNP | TOP2A 206/4885POLB 15/4885TK1 123/4885 |
| US-12195493-B2 | Reversibly blocked nucleoside analogues and their use | NSUN2, NME2, ADAR | TOP2A 92/4885POLB 6/4885TK1 61/4885 |
| US-12503730-B2 | Detectable nucleotide analogues | NT5C3B, NUDT1, RNGTT | TOP2A 322/4885POLB 14/4885TK1 137/4885 |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | TOP2A 228/4885POLB 16/4885TK1 37/4885 |
| US-12187758-B2 | Compounds and methods for treating disease | EHMT1, POLRMT, RNASE1 | TOP2A 228/4885POLB 16/4885TK1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.